VRML Share Price

Open 1.19 Change Price %
High 1.20 1 Day -0.01 -0.83
Low 1.19 1 Week 0.01 0.84
Close 1.20 1 Month 0.28 30.43
Volume 1846 1 Year -0.68 -36.17
52 Week High 1.98
52 Week Low 0.76
VRML Important Levels
Resistance 2 1.21
Resistance 1 1.21
Pivot 1.20
Support 1 1.19
Support 2 1.19
NASDAQ USA Most Active Stocks
SIRI 4.30 -5.49%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
QQQ 115.70 0.20%
WRES 0.09 0.00%
More..
NASDAQ USA Top Gainers Stocks
QKLS 0.21 110.00%
LOCM 0.09 50.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PERF 1.90 22.58%
ASNA 7.01 20.24%
SBSA 4.60 17.95%
CEMP 7.55 15.27%
XXIA 15.55 14.76%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
VALV 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
RITT 0.06 -45.45%
DVOX 0.05 -44.44%
More..

Vermillion, Inc. (NASDAQ: VRML)

VRML Technical Analysis 1.5
As on 2nd Dec 2016 VRML Share Price closed @ 1.20 and we RECOMMEND Sell for LONG-TERM with Stoploss of 1.32 & Buy for SHORT-TERM with Stoploss of 1.16 we also expect STOCK to react on Following IMPORTANT LEVELS.
VRML Target for December
1st Target up-side 1.48
2nd Target up-side 1.67
3rd Target up-side 1.87
1st Target down-side 0.92
2nd Target down-side 0.73
3rd Target down-side 0.53
VRML Other Details
Segment EQ
Market Capital 18049096.00
Sector Healthcare
Industry Diagnostic Substances
Offical website http://www.vermillion.com
VRML Address
VRML
Building III
Suite 100
Austin, TX 78738
United States
Phone: 512-519-0400
Fax: 512-439-6980
Interactive Technical Analysis Chart Vermillion, Inc. ( VRML NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Vermillion, Inc.
VRML Business Profile
Vermillion, Inc. is engaged in the discovery, development and commercialization of diagnostic tests that helps physicians diagnose, treat and improve outcomes for patients. The Company's tests are intended to help guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, to perform additional testing, or to assist in the selection of therapy. The Company combines multiple biomarkers into a single, reportable index score. The Company concentrates its development of diagnostic tests in the fields of oncology, cardiology and women�s health, with the initial focuses on ovarian cancer.The Company's product, OVA1, addresses a clear unmet clinical need, namely the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor.In addition to OVA1, the Company has development programs in other clinical aspects of ovarian cancer as well as in peripheral arterial disease.